DANIEL CHUEH: Open Payments
NPI 1174589642 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$15,440 in 102 payments from 14 companies in 2025. Trend: 2023 $18,130 · 2024 $36,363 · 2025 $15,440
Speaker / faculty: $10,041Food & beverage: $2,742Consulting: $2,646Travel & lodging: $12
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $11,854 |
| Otsuka America Pharmaceutical, Inc. | 11 | $1,558 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $554 |
| E.R. Squibb & Sons, L.L.C. | 12 | $275 |
| ABBVIE INC. | 8 | $185 |
| Alkermes, Inc. | 4 | $180 |
| Axsome Therapeutics, Inc. | 3 | $174 |
| Vanda Pharmaceuticals Inc. | 12 | $174 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $154 |
| Janssen Pharmaceuticals, Inc | 1 | $144 |
Products named: UZEDY, REXULTI, CAPLYTA, COBENFY, VRAYLAR, Auvelity, FANAPT, SPRAVATO.
Industry payments across CA — which companies pay providers there.
